Gyre Therapeutics (NASDAQ:GYRE) Announces Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Gyre Therapeutics (NASDAQ:GYRE) released its earnings results on Thursday. The company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04), Zacks reports. Gyre Therapeutics had a net margin of 4.31% and a return on equity of 11.25%. The business had revenue of $37.20 million for the quarter, compared to the consensus estimate of $36.30 million.

Gyre Therapeutics Price Performance

GYRE stock traded down $0.25 during trading on Friday, hitting $7.55. The stock had a trading volume of 138,333 shares, compared to its average volume of 114,571. The stock has a market capitalization of $727.29 million, a P/E ratio of 755.76 and a beta of 1.97. The company’s 50-day moving average price is $7.96 and its two-hundred day moving average price is $7.78. Gyre Therapeutics has a twelve month low of $6.11 and a twelve month high of $12.62.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of GYRE. Barclays PLC grew its holdings in Gyre Therapeutics by 38.3% in the 4th quarter. Barclays PLC now owns 18,531 shares of the company’s stock valued at $131,000 after buying an additional 5,135 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Gyre Therapeutics by 37.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock worth $1,194,000 after purchasing an additional 45,772 shares during the last quarter. State Street Corp raised its stake in Gyre Therapeutics by 10.7% during the fourth quarter. State Street Corp now owns 202,225 shares of the company’s stock worth $1,428,000 after purchasing an additional 19,472 shares during the period. Wells Fargo & Company MN raised its stake in Gyre Therapeutics by 132.4% during the fourth quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock worth $91,000 after purchasing an additional 7,361 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new position in Gyre Therapeutics in the 4th quarter valued at about $77,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GYRE has been the topic of several research analyst reports. Zacks Research raised shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, November 14th. Wall Street Zen lowered shares of Gyre Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Gyre Therapeutics in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $17.00.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.